SFM
CYCN icon

Sphera Funds Management’s Cyclerion Therapeutics CYCN Stock Holding History

Sphera Funds Management’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-6,249
Closed -$331K – 96
2020
Q1 		$331K Buy
+6,249
New +$446K 0.04% 72

Other funds holding CYCN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sphera Funds Management's CYCN Position: Q2 2020 in Review

Sphera Funds Management sold out of Cyclerion Therapeutics (CYCN) in Q2 2020, closing a stake of 6,249 shares — an estimated $331K sold.

Sphera Funds Management first reported a position in CYCN in Q1 2020 and held it in 1 quarter. The position peaked at $331K in Q1 2020. 74 funds tracked by Wall St. Rank hold CYCN as of Q2 2020.

  • Sphera Funds Management reported no remaining Cyclerion Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Sphera Funds Management sold 6,249 Cyclerion Therapeutics shares in Q2 2020, an estimated $331K.
  • Sphera Funds Management first reported a position in Cyclerion Therapeutics in Q1 2020 and held it in 1 quarter.
  • Sphera Funds Management's Cyclerion Therapeutics position peaked at $331K in Q1 2020.
  • 74 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2020.

Based on Sphera Funds Management's 13F filing for Q2 2020, filed 13 Aug 2020.